ALTH Allos Therapeutics, Inc. (MM)

Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that it will report 2007 financial results on Wednesday, February 27, 2008, before the open of the U.S. financial markets. Paul L. Berns, President and Chief Executive Officer, and other members of Allos' senior management will provide a company update and review 2007 results via webcast and conference call on Wednesday, February 27, 2008, at 8:30 a.m. ET. The webcast of this call will be available from the homepage and the investors/media section of the Company's web site, www.allos.com. Alternatively, callers may participate in the conference call by dialing 800-762-8779 (domestic) or 480-248-5081 (international). Participants should reference the Allos Therapeutics conference call. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Friday, March 14, 2008. To access the replay, callers should dial 800-406-7325 (domestic) or 303-590-3030 (international). The passcode is 3834606#. About Allos Therapeutics, Inc. Allos Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer.�The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of lymphoma sub-types. The Company's other product candidate�is RH1, a targeted chemotherapeutic agent currently being evaluated in a Phase 1 trial in patients with advanced solid tumors or non-Hodgkins Lymphoma (NHL). For additional information, please visit the Company�s website at www.allos.com. Safe Harbor Statement The 2007 results press release and conference call will contain forward-looking statements that involve significant risks and uncertainties, including those contained in the "Risk Factors" section of the company's Annual Report on Form 10-K for the year ended December 31, 2006 and in the company's other periodic reports and filings with the Securities and Exchange Commission. Allos is providing the information contained in the press release and conference call as of the date of the release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the press release or the conference call. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected.